JosÃ© C CrispÃ-n

List of Publications by Year
in descending order

107 papers	5,626 citations	71061 41 h-index	79644 73 g-index
112 all docs	112 docs citations	112 times ranked	6006 citing authors

#	Article	IF	Citations
1	Regulation of activated T cell survival in rheumatic autoimmune diseases. Nature Reviews Rheumatology, 2022, 18, 232-244.	3.5	21
2	Dysregulated protein kinase/phosphatase networks in SLE T cells. Clinical Immunology, 2022, 236, 108952.	1.4	1
3	Orbital and periorbital inflammation in VEXAS syndrome. Scandinavian Journal of Rheumatology, 2022, 51, 338-341.	0.6	18
4	Identification of regulatory T cell molecules associated with severity of multiple sclerosis. Multiple Sclerosis Journal, 2021, 27, 1695-1705.	1.4	13
5	T cells. , 2021, , 123-129.		0
6	Fas/FasL Signaling Regulates CD8 Expression During Exposure to Self-Antigens. Frontiers in Immunology, 2021, 12, 635862.	2.2	6
7	Common hematological values predict unfavorable outcomes in hospitalized COVID-19 patients. Clinical Immunology, 2021, 225, 108682.	1.4	18
8	Ethical Considerations in Animal Research: The Principle of 3R's. Revista De Investigacion Clinica, 2021, 73, 199-209.	0.2	23
9	Unwinding the Long Road that leads to Understanding Autoimmunity. Revista De Investigacion Clinica, 2021, 73, 297-301.	0.2	0
10	The helminth-derived peptide GK-1 induces an anti-tumoral CD8 T cell response associated with downregulation of the PD-1/PD-L1 pathway. Clinical Immunology, 2020, 212, 108240.	1.4	5
11	A parallel-group, multicenter randomized, double-blinded, placebo-controlled, phase 2/3, clinical trial to test the efficacy of pyridostigmine bromide at low doses to reduce mortality or invasive mechanical ventilation in adults with severe SARS-CoV-2 infection: the Pyridostigmine In Severe COvid-19 (PISCO) trial protocol. BMC Infectious Diseases, 2020, 20, 765.	1.3	11
12	AMPK Phosphorylation Effect of Genistein Is Independent of GPR30. Current Developments in Nutrition, 2020, 4, nzaa045_117.	0.1	0
13	TCR-Î±/Î² CD4â^' CD8â^' double negative T cells arise from CD8+ T cells. Journal of Leukocyte Biology, 2020, 108, 851-857.	1.5	18
14	Serine/threonine phosphatase PP2A is essential for optimal B cell function. JCI Insight, 2020, 5, .	2.3	9
15	Protein phosphatase 2A B55Î² limits CD8+ T cell lifespan following cytokine withdrawal. Journal of Clinical Investigation, 2020, 130, 5989-6004.	3.9	5
16	Cancer immunosurveillance by CD8 T cells. F1000Research, 2020, 9, 80.	0.8	11
17	Ethical Considerations in Animal Research: The Principle of 3R's. Revista De Investigacion Clinica, 2020, 73, .	0.2	0
18	Gene-function studies in systemic lupus erythematosus. Current Opinion in Rheumatology, 2019, 31, 185-192.	2.0	14

#	Article	IF	Citations
19	Editorial: Mechanisms by Which SLE-Associated Genetic Variants Contribute to SLE Pathogenesis. Frontiers in Immunology, 2019, 10, 2808.	2.2	1
20	T Cells. , 2019, , 116-124.		0
21	PPP2R2B hypermethylation causes acquired apoptosis deficiency in systemic autoimmune diseases. JCI Insight, 2019, 4, .	2.3	14
22	Mechanisms of Tissue Injury in Lupus Nephritis. Trends in Molecular Medicine, 2018, 24, 364-378.	3.5	86
23	Intrathecal anti-suprabasin antibodies in SLE, a cause of local concern?. Clinical Immunology, 2018, 193, 131-132.	1.4	0
24	Intrathecal formation of anticardiolipin antibodies in a patient with SLE-related relapsing longitudinal myelitis: a possible pathogenic connection. Lupus, 2018, 27, 2292-2295.	0.8	2
25	CD47 overexpression is associated with decreased neutrophil apoptosis/phagocytosis and poor prognosis in non-small-cell lung cancer patients. British Journal of Cancer, 2017, 117, 385-397.	2.9	77
26	SLE-Associated Defects Promote Altered T Cell Function. Critical Reviews in Immunology, 2017, 37, 39-58.	1.0	21
27	Add-on Pyridostigmine Enhances CD4+ T-Cell Recovery in HIV-1-Infected Immunological Non-Responders: A Proof-of-Concept Study. Frontiers in Immunology, 2017, 8, 1301.	2.2	13
28	Expression of PD-1/PD-L1 and PD-L2 in peripheral T-cells from non-small cell lung cancer patients. Oncotarget, 2017, 8, 101994-102005.	0.8	72
29	T Cells. , 2016, , 113-119.		0
30	ICER is requisite for Th17 differentiation. Nature Communications, 2016, 7, 12993.	5.8	64
31	Proâ€inflammatory selfâ€reactive TÂcells are found within murine TCRâ€Î±Î²⁺CD4^{â^'}CD8^{â^'}PDâ€1⁺ cells. European Journal of Immunology, 2016, 46, 1383-1391.	1.6	36
32	Phosphatase PP2A is requisite for the function of regulatory T cells. Nature Immunology, 2016, 17, 556-564.	7.0	191
33	FRI0018â€...CAMK4 Inhibition Prevents Recruitment of IL-17 Producing Cells to Target Organs Through CCR6/CCL20 Axis in TH17 Driven Inflammatory Diseases. Annals of the Rheumatic Diseases, 2015, 74, 425.1-425.	0.5	0
34	Complement receptor of the immunoglobulin superfamily reduces murine lupus nephritis and cutaneous disease. Clinical Immunology, 2015, 160, 286-291.	1.4	25
35	Programmed Cell Death 1 and Helios Distinguish TCR-Î±Î²+ Double-Negative (CD4â^'CD8â^') T Cells That Derive from Self-Reactive CD8 T Cells. Journal of Immunology, 2015, 194, 4207-4214.	0.4	53
36	Lessons from SjÃ¶grenâ€™s syndrome etiopathogenesis: Novel cellular and molecular targets. World Journal of Immunology, 2015, 5, 152.	0.5	0

#	Article	IF	Citations
37	Pathogenesis of lupus. , 2015, , 1082-1087.		0
38	Systemic Lupus Erythematosus and Systemic Autoimmunity. , 2014, , .		0
39	KN-93, an inhibitor of calcium/calmodulin-dependent protein kinase IV, promotes generation and function of Foxp3⁺regulatory T cells in MRL/lprmice. Autoimmunity, 2014, 47, 445-450.	1.2	60
40	cAMP Responsive Element Modulator (CREM) Î± Mediates Chromatin Remodeling of CD8 during the Generation of CD3+CD4â^'CD8â^' T Cells. Journal of Biological Chemistry, 2014, 289, 2361-2370.	1.6	66
41	Stat3 promotes IL-10 expression in lupus T cells through trans- activation and chromatin remodeling. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 13457-13462.	3.3	148
42	Epigenetic regulation of cytokine expression in systemic lupus erythematosus with special focus on T cells. Autoimmunity, 2014, 47, 234-241.	1.2	59
43	THU0057â€...Kn-93, an Inhibitor of Calcium/Calmodulin-Dependent Protein Kinase Iv, Promotes Generation and Function of Foxp3+ Regulatory T Cells in Mrl/Lpr Mice. Annals of the Rheumatic Diseases, 2014, 73, 195.3-196.	0.5	0
44	Stat3 and Stat5 govern IL-10 expression in T cells through trans-activation and epigenetic remodelling in health and disease. Molecular and Cellular Pediatrics, 2014, 1, A17.	1.0	0
45	CaMK4-dependent activation of AKT/mTOR and CREM-Î± underlies autoimmunity-associated Th17 imbalance. Journal of Clinical Investigation, 2014, 124, 2234-2245.	3.9	185
46	Systemic Lupus Erythematosus, Pathogenesis. , 2014, , 1178-1184.		0
47	Gene-function studies in systemic lupus erythematosus. Nature Reviews Rheumatology, 2013, 9, 476-484.	3.5	99
48	T Cells. , 2013, , 96-103.		2
49	Brief Report: Increased expression of a short splice variant of CTLAâ€4 exacerbates lupus in MRL/lpr mice. Arthritis and Rheumatism, 2013, 65, 764-769.	6.7	7
50	Protein Phosphatase 2A Enables Expression of Interleukin 17 (IL-17) through Chromatin Remodeling. Journal of Biological Chemistry, 2013, 288, 26775-26784.	1.6	77
51	cAMP-responsive Element Modulator Î± (CREMÎ±) trans-Represses the Transmembrane Glycoprotein CD8 and Contributes to the Generation of CD3+CD4â^'CD8â^' T Cells in Health and Disease. Journal of Biological Chemistry, 2013, 288, 31880-31887.	1.6	53
52	cAMP response element modulator Î± controls IL2 and IL17A expression during CD4 lineage commitment and subset distribution in lupus. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 16606-16611.	3.3	92
53	CREMÎ± overexpression decreases IL-2 production, induces a TH17 phenotype and accelerates autoimmunity. Journal of Molecular Cell Biology, 2012, 4, 121-123.	1.5	34
54	Cutting Edge: Protein Phosphatase 2A Confers Susceptibility to Autoimmune Disease through an IL-17â€“Dependent Mechanism. Journal of Immunology, 2012, 188, 3567-3571.	0.4	51

#	Article	IF	Citations
55	Dysregulation of the serine/threonine phosphatase PP2A contributes to autoimmunity. Arthritis Research and Therapy, 2012, 14, .	1.6	2
56	Human Neurocysticercosis: In Vivo Expansion of Peripheral Regulatory T Cells and Their Recruitment in the Central Nervous System. Journal of Parasitology, 2012, 98, 142-148.	0.3	45
57	Calcium/Calmodulin-Dependent Protein Kinase IV Suppresses IL-2 Production and Regulatory T Cell Activity in Lupus. Journal of Immunology, 2012, 189, 3490-3496.	0.4	91
58	A TWEAK in lupus nephritis. Clinical Immunology, 2012, 145, 139-140.	1.4	3
59	De NovoDonor-Specific HLA Antibody Development and Peripheral<mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" id="M1"><mml:mrow><mml:msup><mml:mrow><mml:mtext>CD4</mml:mtext></mml:mrow><mml:mo>+</mml:mo></mml:msup> in Kidney Transplant Recipients: A Place for Interaction?. Journal of Transplantation, 2012, 2012, 1-8.	0.3	13
60	Phenotype and function of dendritic cells of patients with systemic lupus erythematosus. Clinical Immunology, 2012, 143, 45-50.	1.4	30
61	Neurocysticercosis: local and systemic immune-inflammatory features related to severity. Medical Microbiology and Immunology, 2012, 201, 73-80.	2.6	16
62	The Dysregulation of Cytokine Networks in Systemic Lupus Erythematosus. Journal of Interferon and Cytokine Research, 2011, 31, 769-779.	0.5	120
63	A Novel Inhibitor of the Alternative Pathway of Complement Attenuates Intestinal Ischemia/Reperfusion-Induced Injury. Journal of Surgical Research, 2011, 167, e131-e136.	0.8	30
64	The Role of Interleukin-17 in Systemic Lupus Erythematosus. , 2011, , 391-400.		1
65	T-Cells and Systemic Lupus Erythematosus. , 2011, , 129-142.		0
66	Quantitative and functional profiles of CD4+ lymphocyte subsets in systemic lupus erythematosus patients with lymphopenia. Clinical and Experimental Immunology, 2011, 164, 17-25.	1.1	17
67	Regulatory T cells as modulators of B cell antibody production. Clinical Immunology, 2011, 140, 216-217.	1.4	2
68	Suppression of autoimmunity and organ pathology in lupusâ€prone mice upon inhibition of calcium/calmodulinâ€dependent protein kinase type IV. Arthritis and Rheumatism, 2011, 63, 523-529.	6.7	87
69	Induction of PP2A BÎ², a regulator of IL-2 deprivation-induced T-cell apoptosis, is deficient in systemic lupus erythematosus. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 12443-12448.	3.3	46
70	IL-17-producing T cells in lupus nephritis. Lupus, 2011, 20, 120-124.	0.8	114
71	Pathogenesis of lupus. , 2011, , 1289-1294.e1.		1
72	Interleukin-17-producing T cells in lupus. Current Opinion in Rheumatology, 2010, 22, 499-503.	2.0	80

#	Article	IF	Citations
73	Expression of CD44 variant isoforms CD44v3 and CD44v6 is increased on T cells from patients with systemic lupus erythematosus and is correlated with disease activity. Arthritis and Rheumatism, 2010, 62, 1431-1437.	6.7	76
74	IL-17 in Systemic Lupus Erythematosus. Journal of Biomedicine and Biotechnology, 2010, 2010, 1-4.	3.0	81
75	T cells as therapeutic targets in SLE. Nature Reviews Rheumatology, 2010, 6, 317-325.	3.5	230
76	Pathogenesis of human systemic lupus erythematosus: recent advances. Trends in Molecular Medicine, 2010, 16, 47-57.	3.5	311
77	Acetylcholine-Esterase Inhibitor Pyridostigmine Decreases T Cell Overactivation in Patients Infected by HIV. AIDS Research and Human Retroviruses, 2009, 25, 749-755.	0.5	15
78	Human TCR-Î±Î²+ CD4â^' CD8â^' T Cells Can Derive from CD8+ T Cells and Display an Inflammatory Effector Phenotype. Journal of Immunology, 2009, 183, 4675-4681.	0.4	154
79	Transcriptional regulation of IL-2 in health and autoimmunity. Autoimmunity Reviews, 2009, 8, 190-195.	2.5	89
80	Interleukin 2 and systemic lupus erythematosus. Autoimmunity Reviews, 2009, 9, 34-39.	2.5	48
81	IL-17 producing CD4+ T cells mediate accelerated ischemia/reperfusion-induced injury in autoimmunity-prone mice. Clinical Immunology, 2009, 130, 313-321.	1.4	77
82	Interleukin-17 and systemic lupus erythematosus: current concepts. Clinical and Experimental Immunology, 2009, 157, 209-215.	1.1	193
83	B cells contribute to ischemia/reperfusion-mediated tissue injury. Journal of Autoimmunity, 2009, 32, 195-200.	3.0	39
84	Novel molecular targets in the treatment of systemic lupus erythematosus. Autoimmunity Reviews, 2008, 7, 256-261.	2.5	41
85	T cells and in situ cryoglobulin deposition in the pathogenesis of lupus nephritis. Clinical Immunology, 2008, 128, 1-7.	1.4	34
86	How signaling and gene transcription aberrations dictate the systemic lupus erythematosus T cell phenotype. Trends in Immunology, 2008, 29, 110-115.	2.9	91
87	Quantitative and qualitative normal regulatory T cells are not capable of inducing suppression in SLE patients due to T-cell resistance. Lupus, 2008, 17, 289-294.	0.8	112
88	Expanded Double Negative T Cells in Patients with Systemic Lupus Erythematosus Produce IL-17 and Infiltrate the Kidneys. Journal of Immunology, 2008, 181, 8761-8766.	0.4	678
89	Systemic lupus erythematosus: new molecular targets. Annals of the Rheumatic Diseases, 2007, 66, iii65-iii69.	0.5	22
90	A non-allogeneic stimulus triggers the production of de novo HLA antibodies in healthy adults. Transplant Immunology, 2007, 18, 166-171.	0.6	32

#	Article	IF	Citations
91	The role myeloid dendritic cells play in the pathogenesis of systemic lupus erythematosus. Autoimmunity Reviews, 2007, 6, 450-456.	2.5	42
92	Modulation of In Vivo T Cell Activation by an Acetylcholine-Esterase Inhibitor in Patients Chronically Infected with HIV. Clinical Immunology, 2007, 123, S46.	1.4	0
93	Quantitative and Qualitatively Normal Regulatory T Cells are Not Capable of Inducing Suppression in SLE Patients Due to T Cell Resistance. Clinical Immunology, 2007, 123, S101-S102.	1.4	1
94	Chronic Destructive Elbow Arthropathy Associated With Hydroxyapatite Crystals in a Patient With Systemic Lupus Erythematosus. Journal of Clinical Rheumatology, 2006, 12, 194-195.	0.5	3
95	Moderate and severe neutropenia in patients with systemic lupus erythematosus. Rheumatology, 2006, 45, 994-998.	0.9	51
96	ANCA associated glomerulonephritis in a patient with mixed connective tissue disease. Annals of the Rheumatic Diseases, 2006, 65, 410-411.	0.5	9
97	Letter to the Editor. Lupus, 2005, 14, 495-496.	0.8	35
98	Adult-Onset Still Disease as the Cause of Fever of Unknown Origin. Medicine (United States), 2005, 84, 331-337.	0.4	72
99	Immunoregulatory T cells in autoimmunity. Autoimmunity Reviews, 2004, 3, 45-51.	2.5	21
100	Class I and class II MHC polymorphisms in Mexican patients with BehÃ§etâ€™s disease. Immunology Letters, 2004, 93, 211-215.	1.1	27
101	IL-10 production in B cells is confined to CD154+ cells in patients with systemic lupus erythematosus. Journal of Autoimmunity, 2004, 23, 379-383.	3.0	26
102	Identity loss due to chronic fingertip ischemia. Journal of Rheumatology, 2004, 31, 1222-4.	1.0	4
103	Rheumatologic manifestations of diabetes mellitus. American Journal of Medicine, 2003, 114, 753-757.	0.6	81
104	Quantification of regulatory T cells in patients with systemic lupus erythematosus. Journal of Autoimmunity, 2003, 21, 273-276.	3.0	379
105	Immunoregulatory defects in patients with systemic lupus erythematosus in clinical remission. Lupus, 2003, 12, 386-393.	0.8	21
106	Participation of the CD69 Antigen in the Tâ€Cell Activation Process of Patients with Systemic Lupus Erythematosus. Scandinavian Journal of Immunology, 1998, 48, 196-200.	1.3	50
107	Interleukin-2 and systemic lupus erythematosusâ€”fifteen years later. Lupus, 1998, 7, 214-222.	0.8	22